have an example of a crazy return in my portfolio this week, and it’s getting close to the time that I have to make a decision about it. My remaining position in Shopify (SHOP) April Call Options, on which I’ve already taken a profit in excess of my initial investment, was glowing on my spreadsheet […]
Articles
- Most Relevant
- Most Recent
Here’s the teaser pitch from Lombardi’s Moe Zulfiqar that caught my eye as he shouts out the headline, “A 1,000% Windfall from the New King of Online Retail“… Here’s some more from the first part of the ad, which is sniffing around in an attempt to dig up new subscribers to Lombardi’s Micro-Cap Tech Reporter […]
WORKING TOWARD MORE EFFECTIVE GUN REGULATIONS WITH #NEVERAGAIN#NeverAgain is a new American student-led organization that advocates for tighter regulations to prevent gun violence. It was started in February, 2018, by 20 students at Marjory Stoneman Douglas High School in Parkland, Florida, after 17 people were murdered by a shooter armed with an AR-15 style semi-automatic rifle, and now has tens of thousands […]
The latest ad for The Casey Report caught my eye this week, partly because I thought they might be following in teasing eCobalt (ECSI)… but it turns out that’s not the case, this pitch from E.B. Tucker about the next cobalt bull market being driven by lithium-ion battery demand is all about two other cobalt […]
Well, it’s the beginning of a new year and time for introspection — so I thought I’d revisit some of the older ideas I’ve profiled for the Idea of the Month, and list all of the Ideas in my order of preference today. So first, the list — if I were buying today from the […]
Another month, another big pitch about a biotech stock with a great “P-Value Indicator” from Ernie Tremblay, all in an ad for his Biotech Insider Alert. Should we pay attention? Well, we can hardly avoid noticing it — we’re being battered about the head and neck with the constant email fusillade from Tremblay’s publisher and […]
Ray Blanco seems to love pitching a good “results coming soon” story for his FDA Trader ($1,495, no refunds) newsletter over at Agora, and this one is no different from dozens of others he has touted in the past… though the stock is one I haven’t seen him tease before. OK, fine, yes, I know […]
I may have to add a little dose of guessing to the Thinkolator results on this one, but we’ve had a few folks asking “who beat Amazon?” of late, thanks to this latest Motley Fool ad, so I’m going to give it a try. The ad is for the Motley Fool’s flagship Stock Advisor service, […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]
Today we point the compass toward Santa Claus and head up a few miles to cross the border into Canada, where we find the latest teaser pitch coming in from Motley Fool Canada for their Stock Advisor Canada newsletter… the ad comes from Iain Butler, the Chief Investment Adviser for the Canadian version of the […]
I suppose I should expect this by now — whenever Frank Curzio and the gang put out a teaser for Phase 1 Investor, which is the big-money newsletter from Stansberry & Associates ($5,000/year, though almost always “on sale” at $3,000 when they’re running promos), my inbox gushes like Spindletop. Didn’t matter if it was a […]
This discussion provides the current and future of of Li, G, NAM; H2O and more… After Fukushima REBECCA JOHNSON 24 March 2011 https://www.opendemocracy.net/5050/rebecca-johnson/after-fukushima LONG TSX-V: GGG $0.25 OTCQB: $GPHBF $0.19, July 28, 2016 Graphene 3D Lab Introduces New Type of Single Layer Graphene Material: http://www.graphene3dlab.com/s/news.asp?ReportID=757543&_Type=News&_Title=Graphene-3D-Lab-Introduces-New-Type-of-Single-Layer-Graphene-Material $GLFN – http://galenfeha.com/ and #Gummune … Author: arch1 Comment: http://www.stockgumshoe.com/2016/03/microblog-club-house-for-the-discussion-of-religion-politics-and-other-unmentionables-volume-5/comment-page-17/#comment-4886050 […]
OK, I know, it’s getting a little ridiculous that I still haven’t covered the whole portfolio of stocks with my annual review updates — but for some I’m waiting to see what the quarterly update tells me, and for others, well, I’m just trying to catch up. Here’s what I’ve got for you by way […]
Earlier in the week we took a look at a “short” case for a tech stock, so today I thought I’d spend a few minutes tracking down some of Louis Navellier’s favorite picks to buy on what he predicts will be blockbuster earnings in the days ahead. Navellier has a bunch of both fans and […]
The Investorplace Media folks have gotten awfully quiet lately — I haven’t seen many over-the-top pitches from Louis Navellier or Hilary Kramer of late, and other big promisers like Robert Hsu and Nancy Zambell have moved on or shut down their letters. But over the last couple of days I’ve been getting questions about the […]
The talk of trade war with China is bringing the idea of Chinese mineral dominance back to the pages of investment teaser ads… we’ve seen several in the last week or two that focus on rare earths, where China remains dominant and might have some extra negotiating leverage in trade disputes, and this latest pitch […]
This ad sounds a little bit like a very popular one we looked at a few months back — then, it was for $1 “Silver Shots”, and it was a teaser for a leveraged derivative trade on silver futures (or, in plainer speak, it was for long-term call options on the SLV ETF). If you […]
I have been on Anatabloc for two months and it has changed my life completely. Anatabloc nutraceutical supplement available at GNC Thyroid Thyroid / Thyroiditis Overview In the USA alone over 70 million THYROID prescriptions are written at a value of about $2 billion; it’s the 4th most prescribed prescriptions for any disease. In the […]
The ides of February are dismal and dreary here in the wet and grey Pioneer Valley of Massachusetts, but we remain hopeful of the sunshine to come. What do I have to share with you, dear Irregulars, as we seek a little brightness to end the week? Well, I do have a few buys to […]
Indulge me for a moment, dear reader — I’m going to wander around thinking about valuation and about short selling, then get into talking about a current situation that closely mirrors some of the long/short pairs trades I’ve done in the past year or so. Then we’ll talk some about gold, since that seems to […]
Which company? This is not Ozempic, Advil, or vitamin D… It’s an entirely new class of medicine that could earn you an absolute FORTUNE. Because not only can it make you smarter, make you stronger, and extend your life span by as much as 20 years… It’s also the most profitable drug in human history… […]
The world of psychedelics was briefly exciting for investors, mostly back around 2019-2020 or so, when everyone was looking for the next version of the cannabis bull market (remember that?)… and as potential for legalization of some drugs, like psilocybin (“magic mushrooms”), seemed to be in the wind, and old hallucinogenic or psychedelic compounds were […]
Almost no professional stock picker or forecaster was expecting that 2023 would be a boom year for the stock market, and I don’t imagine that many folks were predicting that February of 2024 would be the best February for the markets in a decade, but still, we crave predictions. People are endearingly ridiculous, and markets […]
Finally, we take a short break from the A.I. mania to look at something else… this is the start of the pitch from Stansberry for Dr. David Eifrig’s Prosperity Investor(special deal is $2,500 for two years), with the ad introduced by Thomas Carroll, one of the analysts for that letter (John Engel is the other, […]
This article was originally published on August 4, 2022, but Ray Blanco has lately been pitching it as an urgent “last chance” idea because of their March 20, 2023 announcement, so we’re re-sharing this older article so folks can at least know what company he’s talking about (the preclinical results they announced at a conference […]
This week we got a wild mix of news from our Real Money Portfolio companies, with one of our most “boring” stocks announcing some pretty exceptional results… and the “exciting stocks” much more of a mixed bag, about half great and half disappointing. Anything to change our opinion or cause me to update my “max […]
Time to dig into a new teaser ad from Whitney Tilson that we started to see circulating a couple days ago… it’s an ad for Empire Stock Investor, which is the “entry level” paid letter at MarketWise’s Empire Financial ($49 for the first year, renews at $199), and it promises some big stuff — here’s […]
The first version of this story was published on March 4, 2021, and the ad we were covering was also a repeat of a pitch that started appearing about six months earlier. A very similar ad is online now (don’t know if it has been distributed, or if it’s just a lingering old copy), and […]
We’ll start out with the COVID-19 news. Yes, we’re all sick and tired of all COVID-related matters, but it doesn’t much lift our spirits to ignore COVID and pretend that it’s well and truly gone. We know better. It still lurks, and even though case rates and hospitalization rates are way down, people we know […]
I’ve gotten a few questions in recent weeks about a new ad for Curzio Venture Opportunities ($249/month or $2,500/yr, no refunds), which is Frank Curzio’s “high end” upgrade newsletter, focusing on small cap stocks and stuff like junior miners, biotech and private placements. And this one’s a doozy, promoting the idea that a tiny company, […]
Ready for an example of the kind of stupidity on offer at the moment, and a sign of how absurd people are being, at least in the demographic where disposable income has skyrocketed? My daughter is going off to college in a month, which is a wildly expensive life event for almost everybody. We’re fortunate […]
We’ll do a quickie for you today — a reader sent this question in, and was kind enough to even send the answer along with it, so we double-checked, fed his info through the Thinkolator, and I’ll share it with you. The pitch is from Chris Wood, dangling some bait to entice subscribers to his […]
My previous posting on Alzheimer’s focused on ways to avoid the most dire consequences of the disease in the absence of proven pharmaceutical interventions. The common assumption about disease management is that treatment begins when we develop symptoms. Then we go to the doctor, who most likely prescribes a course of treatment which probably includes […]
So… what’s going on this week? A bit of news to pass along first… Shopify (SHOP) shareholders did approve the stock split and “founder share” issued to Tobi Lutke (to maintain his voting control at 40% of the company), so the 10-for-1 stock split will take place after the close on June 28 — you’ll […]
The last time Doc Gumshoe surveyed the Alzheimer’s landscape, the most prominent feature was the FDA’s approval – misguided, I thought – of Biogen’s Aduhelm (aducanumab) and the consequences this would have for everybody’s Medicare B premium. Sure enough, on November 12, 2021, the Centers for Medicare and Medicaid Services (CMS) confirmed the prediction that […]
What’s going on right now? Well, pretty much the same thing that has been going on for the past few months — inflation is raging and freaking out the Federal Reserve, which is getting more assertive in trying to slow the economy to slow that inflation, and for whatever reason the logjam was loosened a […]
In a week that created some pretty massive tumult among the growth stocks I own, I’m going to start today’s note on a very different topic. Don’t worry, we’ll get to Shopify and Roku and Fastly and all the others, but first, something that helps make the heart rate a little steadier. I just made […]
Price targets are starting to come down for a great many stocks these days, and that’s a reminder that analysts, who issue those price targets, essentially do the same thing you and I do: They try to figure out how much money a company is going to make in the future, and then decide what […]
I very rarely get asked about teaser pitches from outside the US and Canada, even though the financial publishing model has certainly migrated to most of the developed markets in the world… so when someone asks about a teaser pitch from another country, it catches my attention. And that leads us to today’s article. The […]
I bought Lspd at $30 usd & then at $15 usd. I sold out at $90 usd. I believe it can be the next Shopify, but also think it could slide further due to the short report scare, supply chain issues ruining their earnings & overall down market. Should I wait for my predicted slide […]